Nutritional interventions in cardiovascular disease: New challenges and opportunities

Current Atherosclerosis Reports

Volumn 2, Issue 6, 2000, Pages 515-520

  Pearson, Thomas A ^a   Osorio, Diana ^a   Brown, Kecia ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

825T Allele; Coronary Heart Disease Mortality; Ischemic Heart Disease Mortality; Nutritional Intervention; Nutritional Strategy

Indexed keywords

CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; DIET; ECONOMICS; EDUCATION; HEALTH FOOD; HUMAN; NUTRITION; PATIENT EDUCATION; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DIET; HEALTH FOOD; HUMANS; NUTRITION PHYSIOLOGY; PATIENT EDUCATION; RISK FACTORS;

EID: 0034326343     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-000-0052-x     Document Type: Article

References (30)

1. Ad Hoc Committee on Health Research Relating to Future Intervention Options: Investing in Health Research and Development, Geneva, World Health Organization, 1996:1-18.
2. Byers T, Anda R, McQueen D, et al.: The correspondence between coronary heart disease mortality and risk factors prevalence among states in the United States, 1991–1992. Prev Med 1998, 27:311–316. DOI: 10.1006/pmed.1998.0303
3. Grundy SM, Balady GJ, Criqui MH, et al.: Guide to primary prevention of cardiovascular diseases: a statement for healthcare professionals from the Task Force on Risk Reduction. Circulation 1997, 95:2329–2331.
4. Goldman L, Cook EF: The decline in ischemic heart disease mortality rates: an analysis of the cooperative effects of medical interventions and changes in lifestyle. Ann Intern Med 1984, 101:828–836.
5. Smith SC Jr, Greenland P, Grundy SM: Preventive Cardiology V: beyond secondary prevention: identifying the high-risk patient for primary prevention. Circulation 2000, 101:111–116.
6. Barker DJP: The intrauterine origins of cardiovascular and obstructive lung disease in adult life: the Marc Daniels Lecture 1990. J Roy Coll Physicians, London 1991, 25:129–133.
7. Barker DJP, Winter PD, Osmond C, et al.: Weight in infancy and death from ischaemic heart disease. Lancet 1989, 2:577–580. DOI: 10.1016/S0140-6736(89)90710-1
8. Barker DJP: Early growth and cardiovascular disease. Arch Dis Child 1999, 80:305–309. DOI: 10.1136/adc.80.4.305
9. Hall EF, McKeigue PM: Fetal origins of coronary heart disease. Evidence-based Cardiovascular Med 1999, 3:87–88. DOI: 10.1054/ebcm.1999.0268
10. Ravelli ACJ, van der Meulen JHP, Osmond C, et al.: Infant feeding and adult glucose tolerance, lipid profile, blood pressure, and obesity. Arch Dis Child 2000, 82:248–252. DOI: 10.1136/adc.82.3.248
11. Forsen T, Eriksson JG, Tuomilehto J, et al.: Growth in utero and during childhood among women who develop coronary heart disease: longitudinal study. BMJ 1999, 319:1403–1407.
12. Eriksson JG, T, Forsen J, Tuomilehto et al.: Catch-up growth in childhood and death from coronary disease: longitudinal study. BMJ 1999, 318:427–431.
13. Velazquez A, Bourges H: Implications of the Human Genome Project for understanding gene-environment interactions. Nutr Rev 1999, 57:S39-S42. DOI: 10.1111/j.1753-4887.1999.tb01786.x
14. Simopoulos AP: Genetic variation and nutrition. Nutr Rev 1999, 57:S10-S19. DOI: 10.1111/j.1753-4887.1999.tb01783.x
15. Cobb MM, Teitlebaum H, Risch N, et al.: Influence of dietary fat, apolipoprotein E phenotype, and sex on plasma lipoprotein levels. Circulation 1992, 86:849–857.
16. Uusitupa MIJ, Ruuskanen E, Makenen E, et al.: A controlled study on the effect of beta-glucan-rich oat bran on serum lipids in hypercholesterolemic subjects: relation to apolipoprotein E phenotype. J Am Coll Nutr 1992, 11:651–659.
17. Neel JV: The ‘thrifty genotype’ in 1998. Nutr Rev 1999, 57:S2-S9. DOI: 10.1111/j.1753-4887.1999.tb01782.x
18. Siffert W, Forster P, Jockel K-H, et al.: Worldwide ethnic distribution of the G protein b3 subunit 825 T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol 1999, 10:1921–1930.
19. Dong Y, Zhu H, Signella GA, et al.: Association between the C825T polymorphism of the G protein b3-subunit gene and hypertension in blacks. Hypertension 1999, 34:1193–1196.
20. Gutersohn A, Naber C, Muller N, et al.: G protein b3-subunit 825 TT genotype and post-pregnancy weight retention. Lancet 2000, 355:1240–1241. DOI: 10.1016/S0140-6736(00)02093-6
21. Pearson TA, Laurora I, Chu H, Kafonek S: The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000, 160:459–467. DOI: 10.1001/archinte.160.4.459
22. Pearson TA: Comprehensive Cardiovascular Medicine. Edited by Topol EJ. Philadelphia: Lippincott-Raven; 1998:297–311.
23. Cooke JP: Nutriceuticals for cardiovascular health. Am J Cardiol 1998, 82:43S-45S.
24. Jones PJH: Comparable efficacy of hydrogenated versus nonhydrogenated plant-sterol esters on circulating cholesterol levels in humans. Nutr Rev 1998, 56:245–252. DOI: 10.1111/j.1753-4887.1998.tb01756.x
25. Westrate JA, Meijer GW: Plant sterol-enriched margarines and reduction of plasma total and LDL-cholesterol concentrations in normocholesterolemic and hypercholesterolemic subjects. Eur J Nutr 1998, 52:334–343. DOI: 10.1038/sj.ejcn.1600559
26. Pearson TA, Lester ML: Nonpharmacologic management of lipid disorders: Reducing ‘bad’ cholesterol. Strategic Med 1998, 2:33–38.
27. Sempos CT, Cleeman JI, Carroll MD, et al.: Prevalence of high blood cholesterol among US adults. JAMA 1993, 269:3009–3014. DOI: 10.1001/jama.269.23.3009
28. Downs JR, Clearfield M, Weiss S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of the AFCAPS/TexCAPS. JAMA 1998, 279:1615–1622. DOI: 10.1001/jama.279.20.1615
29. Pearson TA: Lipid-lowering therapy in low risk patients. JAMA 1998, 279:1659–1661. DOI: 10.1001/jama.279.20.1659
30. Zatonski WA, McMichael AJ, Powles JW: Ecological study of reasons for sharp decline in mortality from ischemic heart disease in Poland since 1991. BMJ 1998, 316:1047–1051.